Imaging Diagnostic Systems
Imaging Diagnostic Systems, Inc. (OTC: IMDS) is a medical device company that developed the CT Laser Mammography (CTLm) system — a radiation-free, three-dimensional breast imaging technology that uses near-infrared laser light rather than X-rays to generate tomographic images of breast tissue, offering a potential imaging alternative for women seeking breast cancer screening without radiation exposure. According to its website at imds.com, the CTLm system uses optical computed tomography technology to map the internal structure of the breast based on the differential light scattering and absorption characteristics of different breast tissue types — including the increased blood vessel density and metabolic activity associated with malignant tumors — producing three-dimensional images that may help identify suspicious areas for further evaluation. The system's radiation-free operation could make it particularly valuable for women who require frequent breast imaging but wish to minimize cumulative radiation exposure from conventional X-ray mammography.
Imaging Diagnostic Systems' CTLm technology, described at imds.com, represents a fundamentally different approach to breast imaging than X-ray mammography, ultrasound, or MRI — the three modalities most commonly used for breast cancer detection — using the optical properties of near-infrared light to characterize breast tissue without ionizing radiation. The system's three-dimensional imaging capability provides a volumetric view of breast tissue that may provide complementary information to planar X-ray mammography images. Imaging Diagnostic Systems has pursued regulatory clearances for the CTLm system in the United States and internationally, engaging with the FDA and international regulatory authorities on the clinical evidence requirements for breast imaging devices that make diagnostic performance claims.
Imaging Diagnostic Systems is a development-stage medical device company that has pursued the commercialization of its CTLm breast imaging technology through regulatory approval processes, clinical evidence generation, and market development activities. According to imds.com, the company continues to advance its regulatory strategy and clinical development activities in support of its commercialization objectives for the CTLm system. Imaging Diagnostic Systems' combination of optical CT mammography technology, radiation-free breast imaging approach, three-dimensional volumetric imaging capability, and regulatory development pathway reflects its positioning as an innovative medical imaging company seeking to establish a new modality in the breast cancer screening and diagnostic imaging market.